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Yellow  Fever  virus  (YFV)  is an important  human  pathogen  in  tropical  areas  of  Africa  and  South  America.
Although  an  efﬁcient  vaccine  is  available  and  has  been  used  since  the  early  1940s,  sylvatic  YFV  transmis-
sion  still  occurs  in forested  areas  where  anthropogenic  actions  are  present,  such  as  mineral  extraction,
rearing  livestock  and  agriculture,  and  ecological  tourism.  In this  context,  two  distinct  techniques  based
on the  RT-PCR  derived  method  have  been  previously  developed,  however  both  methods  are  expensive
due  to  the use of  thermo  cyclers  and  labeled  probes.  We  developed  isothermal  genome  ampliﬁcation,
which  is a rapid,  sensitive,  speciﬁc  and  low  cost  molecular  approach  for YFV  genome  detection.  This  assayellow fever virus
T-LAMP
enome detection
used a set  of  degenerate  primers  designed  for the  NS1  gene  and was  able  to amplify,  within  30  min  in
isothermal  conditions,  the  YFV  17D  vaccine  strain  derived  from  an  African  wild prototype  strain  (Asibi),
as well  as  ﬁeld  strains  from  Brazil,  other  endemic  countries  from  South  and  Central  America,  and  the
Caribbean.  The  generic  RT-LAMP  assay  could  be helpful  for YFV  surveillance  in  ﬁeld  and rapid  response
during  outbreaks  in endemic  areas.. Introduction
Yellow fever virus (YFV) is an arthropod-borne virus belonging
o the Family Flaviviridae, genus Flavivirus (Dietzgen et al., 2012),
here it is the prototype species. It is one of the most important
uman pathogens in tropical areas of Africa and South America
Ferguson et al., 2010; Jentes et al., 2011; Monath, 2001; Monath
nd Vasconcelos, 2015). The viral genome is composed of a single
tranded, positive sense RNA with approximately 11 kb in length
omposed by 10 genes, three structural (E, prM and E) and seven
on structural (NS) namely NS1, NS2a, NS2b,NS3, NS4, NS4b and
S5, which encodes ten proteins with the same name, and the
pen reading frame is ﬂanked by two non-coding regions (NCR)
Dietzgen et al., 2012).
∗ Corresponding author.
E-mail addresses: marcionunes@iec.pa.gov.br,
arcionunesbrasil@yahoo.com.br (M.R.T. Nunes).
1 These authors contributed equally.
ttp://dx.doi.org/10.1016/j.jviromet.2015.10.003
166-0934/© 2015 Elsevier B.V. All rights reserved.©  2015  Elsevier  B.V.  All  rights  reserved.
YFV is the etiological agent of yellow fever, an ancient arbovi-
ral disease that originated in Africa and was introduced into the
Americas during the slave’s trade in the 17th century (Bryant
et al., 2007; Nunes et al., 2012). YFV is maintained in nature in
Africa through three distinct cycles (urban, sylvatic and interme-
diate) and in Americas through two  different cycles (urban and
sylvatic). In Africa, YFV is mainly transmitted by the Aedes sp.
mosquitoes, viz. Aedes africanus, Aedes furcifur and Aedes simpsoni.
Aedes aegypti, Haemagogus leucocelaenus and Haemagogus janthi-
nomys are the main vectors in the Americas (Ferguson et al.,
2010; Monath, 2001; Gardner and Ryman, 2010; Cardoso et al.,
2010).
Approximately 85% of YFV infections are asymptomatic or mild,
and are characterized by sudden onset of fever, chills, severe
headache, back pain, general arthralgia, nausea, vomiting, fatigue,
and weakness with a clinical picture that resembles dengue or
inﬂuenza. The classic severe picture is detected in about 15%
of infected individuals; these patients present with fever, jaun-
dice, hemorrhagic diathesis, and eventually shock, and failure of
multiple organs especially liver and renal failure that result in case-
fatality rates (CFR) of about 50%. The overall CFR of yellow fever is
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0–20% (Monath and Vasconcelos, 2015; Vasconcelos, 2003) With
he strong vector control measures during introduction of the YFV
accine in 1942 (Frierson, 2010; Norrby, 2007), the disease was
argely controlled in urban areas of tropical America. However cases
r limited outbreaks of sylvatic yellow fever are still detected in
orested areas of the Amazon region and central region of Brazil
ue to exposure of susceptible (non immunized) people to the virus
n endemic areas, and also to disruption of natural ecosystems in
hese areas (Vasconcelos et al., 2001). Cases or clusters of urban yel-
ow fever were detected in Bolivia and Paraguay in 1997 and 2009
espectively, after several decades of absence of yellow fever urban
ases (Ferguson et al., 2010; Monath and Vasconcelos, 2015; Van
er Stuyft et al., 1999). Although of great public health importance,
he majority of molecular test protocols developed for yellow fever
se probes, thermo cyclers (Dash et al., 2012; Nunes et al., 2011;
eidmann et al., 2010) or have been developed for African Yellow
ever strains (Domingo et al., 2012; Escadafal et al., 2014; Kwallah
t al., 2013).
The isothermal approach is a simple method that combines a
et of non-labeled primers, conventional deoxynucleotides and a
peciﬁc polymerase able to unfold the double DNA strand (Notomi
t al., 2000). The Reverse Transcription Loop-mediated Isother-
al  Ampliﬁcation (RT-LAMP) has been previously developed to
etect other viruses including inﬂuenza and various other distinct
rboviruses viz. dengue (DENV-1 to 4), West Nile, Chikungunya and
apanese Encephalitis viruses, as well as for African YFV strains
Kalvatchev et al., 2010; Lu et al., 2012; Parida et al., 2004; Poon
t al., 2005; Toriniwa and Komiya, 2006). This approach has been
sed as an alternative method for genome detection. It is low-
ost, rapid, accurate and sensitive (Mori and Notomi, 2009). In
his work, a total of 43 YFV complete genomes retrieved from
he GenBank database were used to develop the RT-LAMP assay
RT-dLAMP) with degenerate primers. This approach was compared
ith previous speciﬁc African strain RT-LAMP method (RT-sLAMP),
T-PCR, RT-hemi-nested-PCR, RT-qPCR, and virus isolation. The
urrent method using degenerate primers was able to detect all
iral isolates recovered from human cases, non-human primates
nd mosquitoes, as well as YFV samples obtained from experimen-
ally infected hamsters.
. Material and methods
.1. Ethics statements
The study protocol was approved by the Animal Care Ethics
ommittee of the Evandro Chagas Institute. The experiments
bserved the principles of the Brazilian Laws and Regulation,
nd the authorization for use was obtained through the protocol
061/2009. VERO cells used in the study were provided by the cell
ulture collection of the Department of Arbovirology and Hemor-
hagic Fevers, World Health Organization Collaborating Center and
ational Reference Center for Training and Research in Arbovirus,
nanindeua, Para, Brazil. All procedures involving virus strains
ere performed in BSL2/BSL3 facilities under the National Biosafety
ules and the Institutional Biocontainment manual (Evandro Cha-
as Institute, Brazilian Ministry of Health, Brasília; Editora do
inistério da Saúde, 2015. 134 p, protocol no. BR275.1; PCIEC2015).
.2. Panel of RNA samples
A total of 130 RNA samples were prepared, corresponding to
5 samples obtained from low passage YFV strains isolated in
ewborn mice and passed once in VERO cells, 25 RNA samples
btained from DENV (5 DENV-1, 5 DENV-2, 5 DENV-3, and 5 DENV-
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virus, Cacipacoré, virus, Ilhéus virus, Saint Louis encephalitis virus,
and Naranjal-like virus), 15 RNA samples from supernatants VERO
cells infected with Oropouche virus (OROV), 15 RNAs obtained
from supernatants of VERO cells infected with Mayaro virus, and
ﬁve negative controls corresponding to RNA extracted from non
infected VERO cells. YFV strains from South American countries
(except Brazil) and Caribbean region (Table 1) were cultured at
the Department of Pathology, University of Texas Medical Branch,
Galveston, and used for RNA extraction using the Trizol-Qiagen pro-
tocol (Qiagen, 2003; Rio et al., 2010). Total RNA samples were sent
to the Center for Technological Innovation (CTI), Evandro Chagas
Institute, Ministry of Health, Brazil. YFV Brazilian strains were cul-
tured in the Department of Arbovirology and Hemorrhagic Fevers,
Evandro Chagas Institute using Biosafety Level 3 (BSL3) facilities,
and RNA samples were obtained at the CTI, Genomic Core, as previ-
ously described (Qiagen, 2003; Rio et al., 2010). RNA samples were
used for RT-LAMP using degenerate primers (RT-dLAMP) evalua-
tion in comparison to four other methods: RT-Hemi-Nested-PCR,
RT-PCR, RT-qPCR (Nunes et al., 2011) and with the current RT-
LAMP assay based on NS1 gene sequence of YFV 17D strain hereafter
named as RT-speciﬁc LAMP (RT-sLAMP) (Khunthong et al., 2013).
2.3. Hamster (Mesocricetus auratus) samples
A total of 120 young hamsters (10-days old) were divided in
two main groups named YFV group and non YFV group, composed
of 60 animals per group. The YFV group was used for experimen-
tal infection with the BeH 111 YFV strain (Brazilian prototype
strain) provided by the Department of Arbovirology and Hemor-
rhagic Fevers, while the non YFV group was used as a control group.
The experiments were conducted in BSL3 facilities according to the
Institutional Biosafety rules and approved by the Ethics Committee
on experiments with animals (CEUA/IEC). Hamsters were infected
by intraperitoneal route with a virus dose of 1.9 × 105 in a volume
of 0.2 mL,  separated in cages with six animals each and observed
daily for a period of 10 days. Blood samples were collected daily
from both groups (YFV and non YFV groups) between days 1–10
post infection. Blood samples were used to obtain sera used for
RNA extraction and for testing the RT-dLAMP and other molecular
methods.
2.4. Primer design
Speciﬁc set of primers were designed based on 43 YFV com-
plete genomes obtained from YFV isolates from Brazil (n = 12),
Africa (n = 30), and Trinidad (n = 01), available at the GenBank
database (http://www.ncbi.org.nih.com) using the online open
source Primer Explores V.4 software (http://primerexplorer.jp/e/
). The sequences were grouped into three distinct clusters based on
geographic locations in South American group, Central American
and the Caribbean group, and African group, and were aligned using
the Geneious v. R-7 (Kearse et al., 2012). Consensus sequences for
each of the established YFV groups were used for re-alignment and
production of a unique consensus of YFV sequences. Degenerate set
of primers were designed and denominated YFVF3 outer primer
(TCCACACCYTGGAGRCAYTR), YFV B3 reverse primer (GYCCAT-
CACAGYYGCCRTCA), YFV Fic (GRCCTCCGATTGAYCTCGGC+TTT),
YFV F2 forward inner primer (ARTGTGARTGGCCRCTGAC), BIP
reverse inner primer YFV B2 (GGTYCAGACRAACGGACCTTGG+TTT),
BIP reverse inner primer B1c (YCCTGGGCAAGCTTCTCT), YFV LF
forward loop primer (CTTCAACTGATGTTCCAATCGTATG), YFV LB
reverse loop primer (ATGCAGGTRCCACTAGAAGTGA). Primers were
used for RT-dLAMP assays (Fig. 1)
42 M.R.T. Nunes et al. / Journal of Virological Methods 226 (2015) 40–51
Table 1
Yellow fever virus strains and other arboviruses RNAs used for evaluation of RT-dLAMP-PCR assay in comparison to other molecular methods.
Group Reference sample no. Strain Place of isolation Host association No. of samples
YFV group
YFV1 JR 35 Bolivia human
YFV2 FVB-0196 Bolivia human
YFV3 92-99 Bolivia human
YFV4 OBS 8027 Bolivia human
YFV5 OBS 7549 Bolivia human
YFV6 OBS 8026 Bolivia human
YFV7 JSS Brazil human
YFV8 BeAR378600 Brazil Haemagogus sp
YFV9  BeH394880 Brazil human
YFV10 BeH413820 Brazil human
YFV11 BeH422973 Brazil human
YFV12 BeH423602 Brazil human
YFV13 BeH463676 Brazil human
YFV14 BeAR513008 Brazil Sabethes chloropterus
YFV15 BeH526722 Brazil human
YFV16 BeH622205 Brazil human
YFV17 BeH622493 Brazil human
YFV18 BeAR646536 Brazil (Haemagogus leucocelaenus)
YFV19  BeH655417 Brazil human
YFV20 INS 347613 Colombia human
YFV21 V 528A Colombia human
YFV22 INS 382060 Colombia human
YFV23 1337 Ecuador human
YFV24 OBS 5026 Ecuador human
YFV25 1345 Ecuador human
YFV26 OBS 5041 Ecuador human
YFV27 690 French Guyana human
YFV28 Jimenez GML  Panama human
YFV29 Jimenez Panama human
YFV30 OBS 7904 Peru human
YFV31 OBS 2240 Peru human
YFV32 HEB 4248 Peru human
YFV33 OBS 6745 Peru human
YFV34 1362/77 Peru human
YFV35 HEB 4245 Peru human
YFV36 HEB 4224 Peru human
YFV37 IQD 8393 Peru human
YFV38 FMD  1240 Peru human
YFV39 1368-77 Peru human
YFV40 OBS 2250 Peru human
YFV41 ARV 0544 Peru human
YFV42 06-15094-99 Peru human
YFV43 HEB 4246 Peru human
YFV44 1371-77 Peru human
YFV45 ARV 0548 Peru human
YFV46 HEB 4240 Peru human
YFV47 03-5350-98 Peru human
YFV48 1914-81 Peru monkey
YFV49 HEB 4236 Peru human
YFV50 06-13015-99 Peru human
YFV51 #1 Peru human
YFV52 TRVL 4205 Trinidad Monkey (Alouatta seniculus)
YFV53 CAREC 790882 Trinidad mosquito (Haemagogus janthinomys)
YFV54 CAREC 9514929 Trinidad mosquito (Haemagogus janthinomys)
YFV55 SVM 3-18-09 Trinidad Monkey (Alouatta sp)
YFV56 CAREC 891957 Trinidad monkey
YFV57 CAREC M2-09 [09-00-122] Trinidad monkey (Alouatta sp)
YFV58 CAREC 797984 Trinidad human
YFV59 CAREC M3-09 Trinidad monkey (Alouatta sp)
YFV60 Trinidad monkey (Alouatta sp)
YFV61 PHO 42 8? H Venezuela human
YFV62 P128 MC Venezuela Monkey (Alouatta seniculus)
YFV63 INH 35708 Venezuela human
YFV64 INH-35720 Venezuela human
YFV  65 17DD ASIBI derived vaccine strain NA 65
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Table  1 (Continued)
Group Reference sample no. Strain Place of isolation Host association No. of samples
Non YFV group
NYFV1 DENV-1 (H547625) Brazil human
NYFV2 DENV-1 (H550175) Brazil human
NYFV3 DENV-1 (H551022) Brazil human
NYFV4 DENV-1 (H611377) Brazil human
NYFV5 DENV-1 (H622822) Brazil human
NYFV6 DENV-2 (H 674704) Brazil human
NYFV7 DENV-2 (H 676618) Brazil human
NYFV8 DENV-2 (H 666995) Brazil human
NYFV9 DENV-2 (H 660059) Brazil human
NYFV10 DENV-2 (H 655259) Brazil human
NYFV11 DENV-3 (H 702980) Brazil human
NYFV12 DENV-3 (H 704582) Brazil human
NYFV13 DENV-3 (H 707629) Brazil human
NYFV14 DENV-3 (H 712120) Brazil human
NYFV15 DENV-3 (H 707877) Brazil human
NYFV16 DENV-4 (H 774846) Brazil human
NYFV17 DENV-4 (H 780090) Brazil human
NYFV18 DENV-4 (H 780120) Brazil human
NYFV19 DENV-4 (H 772846) Brazil human
NYFV20 DENV-4 (H 772852) Brazil human
NYFV21 BSQV (AN 4116) Brazil Alouatta belzebul
NYFV22 CPCV (AN 327600) Brazil Percnostola rufrifrons
NYFV23 ILHV (H 7445) Brazil human
NYFV24 SLEV (AR263600) Brazil Culex declarator
NYFV25 NRLV (AN70170) Brazil Methachirus opossum
NYFV26 OROV (H 389865) Brazil human
NYFV27 OROV (H 390233) Brazil human
NYFV28 OROV (H 390242) Brazil human
NYFV29 OROV (H 472433) Brazil human
NYFV30 OROV (H 472435) Brazil human
NYFV31 OROV (H 472200) Brazil human
NYFV32 OROV (H 472204) Brazil human
NYFV33 OROV (H 475248) Brazil human
NYFV34 OROV (H 498913) Brazil human
NYFV35 OROV (H 505442) Brazil human
NYFV36 OROV (H 505663) Brazil human
NYFV37 OROV (H 505764) Brazil human
NYFV38 OROV (H 505768) Brazil human
NYFV39 OROV (H 505805) Brazil human
NYFV40 OROV (H 504514) Brazil human
NYFV41 MAYV (H 505372) Brazil human
NYFV42 MAYV (H 505465) Brazil human
NYFV43 MAYV (H 394874) Brazil human
NYFV44 MAYV (H 342906) Brazil human
NYFV45 MAYV (H 342925) Brazil human
NYFV46 MAYV (H 342915) Brazil human
NYFV47 MAYV (H 342916) Brazil human
NYFV48 MAYV (AR745587) Brazil Haemagogus janthinomys
NYFV49 MAYV (AR301133) Brazil Haemagogus spp
NYFV50 MAYV (AR327360) Brazil Haemagogus spp
NYFV51 MAYV (AR 344910) Brazil Haemagogus janthinomys
NYFV52 MAYV (H744141) Brazil human
NYFV53 MAYV (H743921) Brazil human
NYFV54 MAYV (H744173) Brazil human
NYFV55 MAYV (AN 345007) Brazil Monkey (Callithrix sp)
NYFV56 NC NA NA
NYFV57 NC NA NA
NYFV58 NC NA NA
NYFV59 NC NA NA
NYFV60 NC NA NA
NYFV61 NC NA NA
NYFV62 NC NA NA
NYFV63 NC NA NA
NYFV64 NC NA NA
NYFV65 NC NA NA 65
Total no. of samples 130
YFV: Yellow fever virus; DENV: Dengue virus; DENV-1: Dengue virus type 1; DENV-2: Dengue virus type 2; DENV-3: Dengue virus type 3; DENV-4: Dengue virus type 4;
BSQV:  Bussuquara virus; CPQV: Cacipacoré virus; ILHV: Ilhéus virus; SLEV: Saint Louis Encephalitis virus; NRLV: Narajal-like virus; OROV: Oropouche virus; MAYV: Mayaro
virus;  NYFV: non-Yellow fever virus; NC: negative control (RNA from non-infected VERO cells); NA: not applied; H: human; AN: animal; AR: arthropod.
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.5. Reverse Transcription Loop-mediated Isothermal
mpliﬁcation using degenerate primers (RT-dLAMP)
The one step RT-dLAMP approach was used for YFV genome
mpliﬁcation. In this case, a set of degenerate primers (Fig. 1) was
sed with the OmniAmpTM RNA & DNA LAMP Kit (http://lucigen.
om/OmniAmp-RNA-and-DNA-LAMP-Kit/) in the following con-
itions: 5 uL of target RNA, 40 pmol of inner primers (YFFIP and
FBIP), 20 pmol of loop primers (YFLF and YFLB), 5 pmol of outer
rimers (YFF3 and YFB3), 800 uM of each dNTP, 12 mM of MgSO4,
 M of Betaine, 1X DNA Polymerase Buffer, 2X OmniAmp DNA Poly-
erase, and DNAse/RNAse free water adjusted to a ﬁnal volume of
5 uL. Reverse transciption was carried out for 30 min  followed by
dditional 30 min  LAMP step run in isothermal condition (60 ◦C)
n a thermoblock heat system (Thermo Scientiﬁc). The ampliﬁed
ene products were separated by electrophoresis in 2% agarose gel
tained with 10,000 × SYBR safe® (Invitrogen) diluted 1:10,000 in
 × TAE (Tris Acetate EDTA) gel and of SYBR® Green I nucleic acid
el stain (10,000X concentrate in DMSO) added to the samples in a
roportion of 1:25. Cross contamination among samples was mini-
ized using individual disposable tips with barrier for each sample,
nd also by pipetting the samples in a class II-B2 biosafety hood,
hich maintains the internal environment in balanced pressure
liminating the aerosol production.
.6. Testing the limit of detection, sensitivity and speciﬁcity
To test the limit of detection of the RT-dLAMP assay for
FV, a standard sample obtained from VERO cells infected with
he prototype YFV strain H111 was used at a concentration of
.9 × 105 PFU/mL. The standard sample was diluted from 10−1 to
0−7 and used for establishment of a standard curve to estimate
he number of viruses in the samples and the limit of viral particles
etected. Each dilution was used to infect six different hamsters via
ntraperitoneal route. Blood samples from each hamster were col-
ected and tested daily between days 0 and 10. The detection was
onsidered successful in a given day if at least 5 of 6 (83.3%) blood
amples were positive for RT-dLAMP using CT = 38.ene of YFV from South America, Central/Caribe region and Africa. Upstream (green)
indicate polymorphism or base degeneration. (For interpretation of the references
Sensitivity and speciﬁcity were determined using the results
obtained from the test panels. True Positive Rates (TPR) and False
Positive Rates (FPR) were calculated according to the following for-
mulas: TPR = TP/(TP + FN) and FPR = FP/(TN + FP) (or 1-speciﬁcity),
where TP is the number of true positive results; FN is the number of
false negative results; FP is the number of false-positive results and
TN is the number true negative results. All calculations were per-
formed using the caret Package (Kuhn, 2008) in the R environment
(R Core Team, 2014).
2.7. Statistical comparison of genome ampliﬁcation assays
For comparison with the RT-dLAMP assay, two  other methods
were selected. The methods corresponded to the RT-Hemi-
NESTED-PCR and the SYBR green one step real time PCR assays
which target the E gene of the YFV genome (Nunes et al., 2011) and
the recently described RT-sLAMP for YFV 17D strain (Khunthong
et al., 2013). The predictive power RT-sLAMP, RT-dLAMP and
qRT-PCR were also evaluated using the Receiver Operating Char-
acteristic (ROC) curve analysis (Kumar and Indrayan, 2011; Pepe,
2000) with an 95% conﬁdence interval (CI) using pROC (Robin et al.,
2011), an open-source R (R Core Team, 2014). The procedures
where TPR and FPR values are closer to 1 and zero, respectively,
represent ideal performance with an AUC = 1 (or 100%) in a ROC
graph.
3. Results
3.1. RT-dLAMP assay and visual analysis
The products of the RT-dLAMP were visualized in both elec-
trophoresis gel (EPG) and by naked eye. Positive results by EPG
were interpreted as ladder bands. For naked eye visualization, pos-
itive samples were observed as ﬂuorescent reactions in the tubes.
Fig. 2 illustrates the positive reactions for the RT-dLAMP PCR assay
using the degenerate YFV NS1 primers.
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Fig. 2. Visualization of RT-dLAMP-PCR products for YFV genome detection. (A) Electrophoresis in 2% agarose gel stained with SYBR® safe. MW:  molecular weight ladder; slots
1–10  correspond to YFV RNAs obtained from wild strains isolated in Bolivia (FVB-0196), Brazil-1 (BeAR378600), Brazil-2 (BeH394880), Colombia (INS 347613), Ecuador (OBS
5026),  French Guyana (690), Panama (Jimenez GML), Peru (OBS 2240), Trinidad (TRVL 4205) and Venezuela (P128 MC), respectively. Slots 11 and 12 correspond to YFV RNAs
obtained from YFV 17D vaccine and BeH 111 strains (positive control), respectively. Slot 13: RNA extracted from non-infected VERO cells (negative control). MW marquer
sizes  are represented in base pairs (bp); (B) visualization using SYBR® green stained samples under UV irradiation. MW:  molecular weight marker; slots 1–6 correspond
to  RNA extracted from strains isolated in Bolivia (FVB-0196), Brazil (BeH394880), Colombia (INS 347613), Ecuador (OBS 5026), Panama (Jimenez GML) and Trinidad (TRVL
4 n; slot
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in the endemic areas (Africa and South America). Poor vector
control and anthropogenic actions in the forest environment, asso-205);  slot 7: 17D YFV vaccine strain; slot 8: BeH 111 YFV Brazilian prototype strai
rrows  indicate the positive pattern (light green) and negative pattern (light orange
he  reader is referred to the web version of this article.)
.2. Determination of true positive and false positive rates and
UCs (area under curve)
The positivity rate for RT-PCR, RT-Hemi Nested-PCR, qRT-PCR,
T-dLAMP and RT-sLAMP were determined using the panel of
amples (Table 1) The numbers of positives in the YFV group
true positive samples) were 40 (61.5%), 61 (93.8%), 65 (100%)
nd 65 (100%), respectively, in 65 tested samples for conven-
ional RT-PCR, RT-Hemi Nested-PCR, qRT-PCR and RT-dLAMP. For
he RT-sLAMP assay, 41 of 65 (63%) were positive. Table 2 sum-
arizes the results for genome detection involving all tested
ssays.
For all tested assays, no false positives were detected in the non
FV group, except for the RT-Hemi-Nested-PCR, where two false
ositives were observed (3.07%).
Based on these results the TPR and FPR were estimated as follow:
T-PCR (TPR = 0.615, FPR = 0), RT-Hemi-Nested PCR (TPR = 0.938,
PR = 0.031); qRT-PCR (TPR = 1, FPR = 0); RT-sLAMP for 17D vaccine
train (TPR = 0, FPR = 0.631); RT-dLAMP using degenerate primers
or YFV (TPR = 1, FPR = 0). Table 3 shows the matrix for all assays.
Comparing the areas under the ROC curves (AUC), the per-
ormances of qRT-PCR and RT-dLAMP were equivalent, with an
UC = 100%, and signiﬁcantly higher then RT-sLAMP, which had an
UC of 91.1% (95% CI, 86.1–96.1%, Fig. 4). 9: RNA obtained from non-infected VERO cells (negative control). Double pointed
g UV irradiation. (For interpretation of the references to color in this ﬁgure legend,
3.3. Limit of detection
The RT-dLAMP showed distinct limits of detection, based on the
sample dilution and days after YFV infection. Undiluted samples
were detectable from day 1 to day 6 with a viral concentration of
1.9 × 105 PFU/mL and CTs ranging from 19 (Day 1) to 36 (Day 6).
For samples diluted from 10−1 to 10−5 (1.9 × 104 to 1.9 PFU/mL),
detections were respectively observed with CTs from 20 (Day 1) to
36 (day 4), CT 31 (day 1) to CT 38 (day 2), CT 33 (day 1) to CT 35
(day 3), CT 35 (day 1) to CT 38 (day 2) and CT 38 (day 1). Samples
diluted from 10−6 (0.19 PFU/ml) to 10−7 (0.019 PFU/mL), reaction
were detected in less than 66% of the samples, and only in day 1
(CT > 38) (Fig. 3). On day 0, none of the dilutions could be detected.
Fig. 3 shows the progression of the chance of detection along the
days.
4. Discussion
Despite an efﬁcient vaccine for control of yellow fever since
the 1940s, the disease still represents a public health concernciated with unplanned, rapid urbanization of cities (Frierson, 2010;
Vasconcelos, 2003; Vasconcelos et al., 2001; Walther et al., 2002),
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Table 2
RNA samples used for comparative analysis of RT-dLAMP-PCR and other molecular methods. YFV: Yellow fever virus; CT: cut-off threshold value (CT = 38).
Groups Virus RNA RT-PCR RT-HemiNested PCR RT-qPCR CT RT-dLAMP PCR CT RT-sLAMP PCR CT Virus isolation
Result Result Result Result Result Result
YFVG
YFV 1 pos pos pos 28 pos 25 pos 34 pos
YFV  2 pos pos pos 25 pos 31 neg 40 pos
YFV  3 pos pos pos 22 pos 22 neg 39 pos
YFV  4 neg pos pos 32 pos 22 neg 38 pos
YFV  5 neg pos pos 31 pos 23 pos 29 pos
YFV  6 pos pos pos 33 pos 26 pos 34 pos
YFV  7 neg pos pos 21 pos 34 neg 39 pos
YFV  8 neg pos pos 21 pos 33 neg 38 pos
YFV  9 pos pos pos 35 pos 31 neg 38 pos
YFV  10 neg pos pos 32 pos 32 neg 38 pos
YFV  11 pos pos pos 29 pos 21 neg 39 pos
YFV  12 pos pos pos 22 pos 24 neg 40 pos
YFV  13 neg pos pos 27 pos 22 neg 40 pos
YFV  14 neg pos pos 22 pos 23 neg 38 pos
YFV  15 neg pos pos 29 pos 21 neg 39 pos
YFV  16 pos pos pos 30 pos 22 neg 40 pos
YFV  17 pos pos pos 31 pos 22 neg 40 pos
YFV  18 neg pos pos 33 pos 30 neg 40 pos
YFV  19 pos pos pos 31 pos 34 neg 38 pos
YFV  20 pos pos pos 28 pos 34 pos 33 pos
YFV  21 pos pos pos 27 pos 35 pos 34 pos
YFV  22 pos pos pos 26 pos 31 pos 37 pos
YFV  23 pos pos pos 31 pos 32 pos 33 pos
YFV  24 neg pos pos 33 pos 32 pos 34 pos
YFV  25 neg neg pos 29 pos 33 pos 37 pos
YFV  26 pos pos pos 27 pos 29 pos 35 pos
YFV  27 pos pos pos 26 pos 29 pos 37 pos
YFV  28 pos pos pos 25 pos 23 pos 32 pos
YFV  29 neg pos pos 22 pos 24 pos 30 pos
YFV  30 neg pos pos 22 pos 23 pos 31 pos
YFV  31 neg pos pos 24 pos 21 pos 33 pos
YFV  32 pos pos pos 31 pos 25 pos 32 pos
YFV  33 pos pos pos 33 pos 34 neg 38 pos
YFV  34 pos pos pos 36 pos 33 neg 38 pos
YFV  35 pos pos pos 33 pos 37 neg 40 pos
YFV  36 neg pos pos 22 pos 31 neg 38 pos
YFV  37 neg neg pos 21 pos 21 pos 33 pos
YFV  38 pos pos pos 20 pos 24 pos 32 pos
YFV  39 pos pos pos 29 pos 26 pos 32 pos
YFV  40 neg neg pos 32 pos 25 pos 32 pos
YFV  41 neg pos pos 22 pos 29 pos 31 pos
YFV  42 pos pos pos 21 pos 31 pos 33 pos
YFV  43 pos pos pos 26 pos 24 pos 34 pos
YFV  44 pos pos pos 27 pos 24 neg 39 pos
YFV  45 pos pos pos 21 pos 21 neg 38 pos
YFV  46 neg pos pos 27 pos 22 neg 38 pos
YFV  47 pos pos pos 22 pos 22 neg 40 pos
YFV  48 neg pos pos 32 pos 34 pos 37 pos
YFV  49 pos pos pos 33 pos 35 pos 36 pos
YFV  50 neg pos pos 28 pos 24 pos 33 pos
YFV  51 neg pos pos 27 pos 25 pos 32 pos
YFV  52 pos pos pos 27 pos 26 pos 31 pos
YFV  53 pos pos pos 26 pos 34 pos 37 pos
YFV  54 neg neg pos 32 pos 35 pos 33 pos
YFV  55 neg pos pos 33 pos 34 pos 30 pos
YFV  56 pos pos pos 33 pos 34 pos 29 pos
YFV  57 pos pos pos 32 pos 32 pos 36 pos
YFV  58 pos pos pos 26 pos 21 pos 34 pos
YFV  59 pos pos pos 24 pos 29 pos 29 pos
YFV  60 pos pos pos 24 pos 22 pos 28 pos
YFV  61 pos pos pos 23 pos 21 pos 32 pos
YFV  62 neg pos pos 21 pos 22 pos 32 pos
YFV  63 pos pos pos 27 pos 31 pos 37 pos
YFV  64 pos pos pos 30 pos 28 pos 33 pos
YFV  65 pos pos pos 31 pos 30 pos 34 pos
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Table  2 (Continued)
Groups Virus RNA RT-PCR RT-HemiNested PCR RT-qPCR CT RT-dLAMP PCR CT RT-sLAMP PCR CT Virus isolation
Result Result Result Result Result Result
NYFVG
NYFV1 neg neg neg 40 neg 39 neg 40 pos
NYFV2  neg neg neg 40 neg 40 neg 40 pos
NYFV3  neg neg neg 40 neg 40 neg 39 pos
NYFV4  neg pos neg 39 neg 38 neg 39 pos
NYFV5  neg neg neg 40 neg 40 neg 39 pos
NYFV6  neg neg neg 40 neg 40 neg 40 pos
NYFV7  neg neg neg 40 neg 40 neg 40 pos
NYFV8  neg neg neg 39 neg 40 neg 40 pos
NYFV9  neg neg neg 38 neg 40 neg 39 pos
NYFV10 neg neg neg 40 neg 40 neg 40 pos
NYFV11 neg neg neg 40 neg 40 neg 40 pos
NYFV12 neg neg neg 40 neg 38 neg 40 pos
NYFV13 neg neg neg 40 neg 40 neg 40 pos
NYFV14 neg neg neg 40 neg 40 neg 40 pos
NYFV15 neg neg neg 40 neg 40 neg 39 pos
NYFV16 neg neg neg 40 neg 40 neg 40 pos
NYFV17 neg neg neg 40 neg 40 neg 40 pos
NYFV18 neg neg neg 38 neg 40 neg 40 pos
NYFV19 neg neg neg 40 neg 40 neg 40 pos
NYFV20 neg neg neg 40 neg 40 neg 40 pos
NYFV21 neg neg neg 40 neg 40 neg 40 pos
NYFV22 neg neg neg 40 neg 39 neg 40 pos
NYFV23 neg neg neg 40 neg 40 neg 40 pos
NYFV24 neg pos neg 40 neg 40 neg 40 pos
NYFV25 neg neg neg 40 neg 40 neg 38 pos
NYFV26 neg neg neg 40 neg 40 neg 40 pos
NYFV27 neg neg neg 40 neg 40 neg 38 pos
NYFV28 neg neg neg 40 neg 40 neg 40 pos
NYFV29 neg neg neg 40 neg 40 neg 40 pos
NYFV30 neg neg neg 40 neg 40 neg 38 pos
NYFV31 neg neg neg 40 neg 40 neg 40 pos
NYFV32 neg neg neg 40 neg 40 neg 40 pos
NYFV33 neg neg neg 39 neg 40 neg 40 pos
NYFV34 neg neg neg 40 neg 39 neg 40 pos
NYFV35 neg neg neg 39 neg 40 neg 40 pos
NYFV36 neg neg neg 39 neg 40 neg 40 pos
NYFV37 neg neg neg 40 neg 40 neg 40 pos
NYFV38 neg neg neg 40 neg 40 neg 40 pos
NYFV39 neg neg neg 40 neg 40 neg 40 pos
NYFV40 neg neg neg 38 neg 38 neg 40 pos
NYFV41 neg neg neg 39 neg 38 neg 39 pos
NYFV42 neg neg neg 40 neg 40 neg 39 pos
NYFV43 neg neg neg 40 neg 40 neg 40 pos
NYFV44 neg neg neg 40 neg 40 neg 40 pos
NYFV45 neg neg neg 40 neg 40 neg 40 pos
NYFV46 neg neg neg 40 neg 40 neg 40 pos
NYFV47 neg neg neg 40 neg 40 neg 40 pos
NYFV48 neg neg neg 40 neg 40 neg 40 pos
NYFV49 neg neg neg 40 neg 40 neg 38 pos
NYFV50 neg neg neg 40 neg 39 neg 40 pos
NYFV51 neg neg neg 40 neg 40 neg 40 pos
NYFV52 neg neg neg 39 neg 40 neg 40 pos
NYFV53 neg neg neg 40 neg 40 neg 40 pos
NYFV54 neg neg neg 40 neg 40 neg 40 pos
NYFV55 neg neg neg 40 neg 40 neg 39 pos
NYFV56 neg neg neg 40 neg 40 neg 40 pos
NYFV57 neg neg neg 40 neg 40 neg 40 pos
NYFV58 neg neg neg 40 neg 40 neg 40 pos
NYFV59 neg neg neg 39 neg 38 neg 40 pos
NYFV60 neg neg neg 38 neg 40 neg 40 pos
NYFV61 neg neg neg 40 neg 40 neg 40 pos
NYFV62 neg neg neg 40 neg 40 neg 40 pos
NYFV63 neg neg neg 40 neg 40 neg 40 pos
NYFV64 neg neg neg 40 neg 38 neg 39 pos
40 
Y ; pos:
a
e
i
2
2
hNYFV65 neg neg neg 
FVG: Yellow fever virus group; NYFV: non-Yellow fever virus group; neg: negative
nd human movements (Woolhouse et al., 2012) from yellow fever
ndemic to non-endemic urban areas have contributed to the
ncreased risk of yellow fever urbanization (Gardner and Ryman,
010; Monath, 2001; Vasconcelos, 2003; Monath and Vasconcelos,
015). In this context, new approaches for detection of yellow fever
ave been developed in recent years (Bae et al., 2003; Dash et al.,neg 40 neg 40 pos
 positive; CT: cut-off threshold value (CT = 38).
2012; Mantel et al., 2008; Weidmann et al., 2010; Nunes et al.,
2011). However, all of them requires the need for a thermal cycler
or real time device, which increases the cost and limits the use of the
test to laboratories with good facilities, equipment, and funding.
More recently, Weidmann et al. (2010), Domingo et al. (2012)
and Escadafal et al. (2014) have developed speciﬁc assays for
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Table 3
Test sensitivity and speciﬁcity for RT-PCR, RT-Nested PCR, RT-qPCR, RT-dLAMP-PCR and RT-sLAMP-PCR assays from 130 RNA samples used in this study, with cutoff CT = 38.
RT-PCR RT-Nested PCR RT-qPCR RT-dLAMP-PCR RT-sLAMP-PCR
True positives 40 61 65 65 41
False  negatives 25 4 0 0 24
True  negatives 65 63 65 65 65
False  positives 0 2 0 0 0
Speciﬁcity 1 0.97 1 1 1
d
o
K
f
o
p
r
c
s
F
s
dSensitivity 0.61 0.94 
etection of YFV genomes. Although robust and easy, the meth-
ds still need the use of labeled probes or speciﬁc equipment.
wallah and co-workers (2013) developed an isothermal approach
or YFV genome detection. This was an important improvement
n ﬁeld assay since the LAMP methodology does not require com-
lex devices (Mori and Notomi, 2009) such as thermo cyclers or
eal time PCR machines which needs mains power supply. In this
ase, the LAMP method requires a simple thermo block heating
upplied by low voltage battery easily and economically obtained
ig. 3. Detection of YFV genome in hamster serum samples using the RT-dLAMP PCR. (A)
ample dilution; (B) chance in percentage of YFV genome detection in hamster serum sam
ilution. CT: cut-off threshold value (CT = 38).1 1 0.63
in general hardware shops. The developed assay for YFV genome
detection described by Kwallah et al. used a set of primers speciﬁc
for the NS1 gene of the YFV 17D vaccine strain which was derived
from the wild YFV ASIBI strain isolated in Ghana in 1927 (Frierson,
2010). This approach succeeded in detecting the YFV genomes
of strains isolated in Africa including the 17D strain. However
YFV strains from other countries were not tested, and there-
fore, the capacity to detect New World YFV strains remains to be
investigated.
 Evaluation of limit of detection according to the day post-infection, CT values and
ples using the RT-dLAMP-PCR assay according to days post-infection and sample
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Fig. 4. ROC curves computed for RT-qPCR, RT-dLAMP-PCR (blue) and RT-sLAMP-PCR assays (red). Conﬁdence interval for RT-sLAMP-PCR ROC curve is shown in salmon color.
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homputed AUCs values are presented as percentage. (For interpretation of the refere
Partial sequences of YFV prM, E, and NS5 genes (Bryant et al.,
007), as well as the complete genome sequences of Brazilian,
frican and Trinidadian YFV strains (Nunes et al., 2012; Pisano
t al., 1999; Stock et al., 2013) have demonstrated a high degree
f genetic variation among YFV isolated in Africa and the Americas.
ndeed, ﬁve and two distinct genetic lineages have been described
espectively in these YFV endemic regions (Bryant et al., 2007;
asconcelos et al., 2004). Due to this genetic variability, we decided
o redesign a set of primers in order to increase the sensitivity and
peciﬁcity to those used by Kwallah et al. (2013) and other authors
Domingo et al., 2012; Escadafal et al., 2014) including degenera-
ions in the consensus sequence (Fig. 1). These degenerations were
sed in order to target all YFV strains available in the Genbank
atabase which included isolates from African, South American,
entral American and the Caribbean regions (Table 1).
The analysis of the RT-dLAMP products demonstrated that the
est succeeded in detecting a wide range of YFV strains obtained
rom new world and one African derived strain (17DD vaccine
train) which were distinctly visualized in both 2% electrophore-
is gel (Fig. 2(a)) and during UV irradiation (Fig. 2(b)), where a very
istinct pattern for positive and negative reactions was observed.
btaining African strains was a limitation for the study, however
he positivity for the 17DD vaccine strain suggests that the RT-
LAMP is also able to detect other YFV African strains. In this case,
urther evaluation using YFV strains isolated in Africa should be
elpful to support this hypothesis.o color in this ﬁgure legend, the reader is referred to the web version of this article.)
The usefulness of a diagnostic test is generally assessed by cal-
culating the sensitivity (TPR) and speciﬁcity (1-FPR), or the positive
predictive value and negative predictive value of the test (DeLong
et al., 1985). We have assessed the sensitivity and speciﬁcity of ﬁve
molecular methods and found 100% positivity for the RT-dLAMP,
indicating that the test was able to detect all true positive sam-
ples (Table 1) included in our assay (Table 2). In comparison with
other tests (conventional RT-PCR, RT-Hemi-Nested-PCR, qRT-PCR
and RT-sLAMP), all tests were speciﬁc. However, the RT-dLAMP
sensitivity was  100% compared to the RT-PCR (61.5%), RT-sLAMP
(63.1%), and RT-Hemi-Nested-PCR (93.8%) (Table 2).
In the case of the conventional RT-PCR, the low sensitivity
(61.5%) may  be explained by the use of primers that amplify a
1 kb long fragment. Efﬁciency on ampliﬁcation of large genomic
fragments could be affected by storage conditions and enzymatic
degradation of RNA or DNA, in particular target sequence (Nunes
et al., 2011). In the case of the RT-sLAMP, analysis of the target
primer binding sites at the NS1 gene proposed by Kwallah and
colleagues (2013) demonstrated that, especially in the F3 outer
primer, F2 Forward inner primer and B3 reverse outer primer bind
sites, three to ﬁve degeneration were found and could be responsi-
ble for the lower test sensitivity (Fig. 1). The efﬁciency with African
strains is explained by the primer speciﬁcity for the YFV 17D vac-
cine strains that was derived from the African wild type Asibi strain.
The RT-dLAMP using degenerate primers were able to amplify
all tested YFV strains isolated in distinct geographic areas and from
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istinct hosts (humans, mosquitoes and monkeys; Tables 1 and 2),
nd had equivalent sensitivity in comparison to the RT-Hemi-
ested-PCR and qRT-PCR (Nunes et al., 2011). In addition, the
valuation of the assay using hamster serum samples infected
ith the YFV Brazilian prototype strain indicates that degenerate
rimers succeeded in detection of YFV genome in low viral titers
nd a higher percentage of detection ranging between 100% and
3% from day 1 to day 4 (Fig. 3(a)). More speciﬁcally, the limit of
etection for the assay was 19 PFU/mL which is equivalent to those
bserved for other methods (Nunes et al., 2011). The ROC method
as been used to evaluate and indicate the performance of a given
est in comparison to other (Kumar and Indrayan, 2011). In case
f the RT-dLAMP, the ROC analysis (Fig. 4) clearly indicates that
t is comparable in performance with RT-qPCR – widely used for
etection of RNA viruses.
The current assay does not use complex equipment, and can
e easily handled by technicians with basic knowledge in sam-
le handling. The absence of thermocyclers and eye visualization
f test results are possible factors that contribute to the low-cost
f the test, facilitating wider range of use in laboratories with
asic facilities. Thus, the RT-dLAMP could be a useful approach for
FV detection during ecologic/epidemiologic investigations in ﬁeld
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